Details of the Drug

General Information of Drug (ID: DMP6SC2)

Drug Name
Irinotecan
Synonyms
Biotecan; Camptosar; Irinotecanum; IRINOTECAN HYDROCHLORIDE Trihydrate; Irinotecan Hcl; Irinotecan hydrochloride; CP0; Biotecan (TN); Campto (TN); Camptosar (TN); Irinotecan (INN); Irinotecan [INN:BAN]; Irinotecanum [INN-Latin]; IRINOTECAN, CPT-11; Camptosar, Campto, CPT-11, Irinotecan; (+)-Irinotecan; (4S)-4,11-DIETHYL-4-HYDROXY-3,14-DIOXO-3,4,12,14-TETRAHYDRO-1H-PYRANO[3',4':6,7]INDOLIZINO[1,2-B]QUINOLIN-9-YL 1,4'-BIPIPERIDINE-1'-CARBOXYLATE; (4S)-4,11-Diethyl-4-hydroxy-3,14-dioxo-4,12-dihydro-1H-pyrano[3,4-f]quinolino[2,3-a]indolizin-9-yl 4-piperidylpiperidinecarboxylate; Irinotecan (TOPO1 inhibitor); Onivyde
Indication
Disease Entry ICD 11 Status REF
Colorectal cancer 2B91.Z Approved [1], [2]
Therapeutic Class
Anticancer Agents
Drug Type
Small molecular drug
Structure
3D MOL 2D MOL
#Ro5 Violations (Lipinski): 1 Molecular Weight (mw) 586.7
Topological Polar Surface Area (xlogp) 3
Rotatable Bond Count (rotbonds) 5
Hydrogen Bond Donor Count (hbonddonor) 1
Hydrogen Bond Acceptor Count (hbondacc) 8
ADMET Property
Absorption AUC
The area under the plot of plasma concentration (AUC) of drug is 10,200 mcgh/L [3]
Absorption Cmax
The maximum plasma concentration (Cmax) of drug is 1660 mcg/L [3]
BDDCS Class
Biopharmaceutics Drug Disposition Classification System (BDDCS) Class 1: high solubility and high permeability [4]
Clearance
The drug present in the plasma can be removed from the body at the rate of 7 mL/min/kg [5]
Elimination
16.7% of drug is excreted from urine in the unchanged form [4]
Half-life
The concentration or amount of drug in body reduced by one-half in 6 - 12 hours [5]
Metabolism
The drug is metabolized via the hepatic [3]
MRTD
The Maximum Recommended Therapeutic Dose (MRTD) of drug that ensured maximising efficacy and moderate side effect is 0.7548 micromolar/kg/day [6]
Unbound Fraction
The unbound fraction of drug in plasma is 0.51% [5]
Vd
Fluid volume that would be required to contain the amount of drug present in the body at the same concentration as in the plasma 3.5 L/kg [5]
Water Solubility
The ability of drug to dissolve in water is measured as 10 mg/mL [4]
Chemical Identifiers
Formula
C33H38N4O6
IUPAC Name
[(19S)-10,19-diethyl-19-hydroxy-14,18-dioxo-17-oxa-3,13-diazapentacyclo[11.8.0.02,11.04,9.015,20]henicosa-1(21),2,4(9),5,7,10,15(20)-heptaen-7-yl] 4-piperidin-1-ylpiperidine-1-carboxylate
Canonical SMILES
CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)[C@@]4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7
InChI
InChI=1S/C33H38N4O6/c1-3-22-23-16-21(43-32(40)36-14-10-20(11-15-36)35-12-6-5-7-13-35)8-9-27(23)34-29-24(22)18-37-28(29)17-26-25(30(37)38)19-42-31(39)33(26,41)4-2/h8-9,16-17,20,41H,3-7,10-15,18-19H2,1-2H3/t33-/m0/s1
InChIKey
UWKQSNNFCGGAFS-XIFFEERXSA-N
Cross-matching ID
PubChem CID
60838
ChEBI ID
CHEBI:80630
CAS Number
97682-44-5
DrugBank ID
DB00762
TTD ID
D07HOB
VARIDT ID
DR00112
INTEDE ID
DR0881

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
DNA topoisomerase I (TOP1) TTGTQHC TOP1_HUMAN Modulator [7]

Drug Transporter (DTP)
DTP Name DTP ID UniProt ID MOA REF
Multidrug resistance-associated protein 5 (ABCC5) DTYVM24 MRP5_HUMAN Substrate [8]
Multidrug resistance-associated protein 2 (ABCC2) DTFI42L MRP2_HUMAN Substrate [9]
Multidrug resistance-associated protein 4 (ABCC4) DTCSGPB MRP4_HUMAN Substrate [10]
Multidrug resistance-associated protein 1 (ABCC1) DTSYQGK MRP1_HUMAN Substrate [11]
Breast cancer resistance protein (ABCG2) DTI7UX6 ABCG2_HUMAN Substrate [12]
P-glycoprotein 1 (ABCB1) DTUGYRD MDR1_HUMAN Substrate [9]

Drug-Metabolizing Enzyme (DME)
DME Name DME ID UniProt ID MOA REF
Cytochrome P450 3A4 (CYP3A4) DE4LYSA CP3A4_HUMAN Substrate [13]
Cytochrome P450 3A5 (CYP3A5) DEIBDNY CP3A5_HUMAN Substrate [14]
Cytochrome P450 2B6 (CYP2B6) DEPKLMQ CP2B6_HUMAN Substrate [15]
Cytochrome P450 3A7 (CYP3A7) DERD86B CP3A7_HUMAN Substrate [16]
Carboxylesterase 1 (CES1)
Main DME 		DEB30C5 EST1_HUMAN Substrate [13]
Carboxylesterase 2 (CES2)
Main DME 		DETHCPD EST2_HUMAN Substrate [17]
Carboxylesterase 3 (CES3)
Main DME 		DEMI4VE EST3_HUMAN Substrate [17]
Beta-glucuronidase (uidA) DE9RA0I BGLR_ECOLI Substrate [18]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

Molecular Expression Atlas of This Drug

The Studied Disease Colorectal cancer
ICD Disease Classification 2B91.Z
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
DNA topoisomerase I (TOP1) DTT TOP1 6.65E-01 0.2 0.39
Multidrug resistance-associated protein 5 (ABCC5) DTP MRP5 3.16E-78 1.01E+00 1.96E+00
P-glycoprotein 1 (ABCB1) DTP P-GP 3.12E-33 -8.30E-01 -1.04E+00
Multidrug resistance-associated protein 1 (ABCC1) DTP MRP1 1.90E-30 1.76E-01 7.31E-01
Breast cancer resistance protein (ABCG2) DTP BCRP 3.87E-47 -1.28E+00 -1.63E+00
Multidrug resistance-associated protein 2 (ABCC2) DTP MRP2 1.02E-08 -5.12E-02 -2.22E-01
Multidrug resistance-associated protein 4 (ABCC4) DTP MRP4 1.26E-03 -4.35E-01 -5.28E-01
Carboxylesterase 2 (CES2) DME CES2 5.70E-09 -2.45E-01 -8.70E-01
Cytochrome P450 2B6 (CYP2B6) DME CYP2B6 2.81E-03 -9.34E-02 -3.57E-01
Carboxylesterase 3 (CES3) DME CES3 1.56E-14 1.28E-01 5.38E-01
Cytochrome P450 3A5 (CYP3A5) DME CYP3A5 3.12E-38 -1.81E+00 -2.01E+00
Carboxylesterase 1 (CES1) DME CES1 1.32E-132 -2.41E+00 -3.96E+00
Cytochrome P450 3A4 (CYP3A4) DME CYP3A4 5.59E-39 -3.76E-01 -1.64E+00
Molecular Expression Atlas (MEA) Jump to Detail Molecular Expression Atlas of This Drug

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Same Disease as Irinotecan
DDI Drug Name DDI Drug ID Severity Mechanism Disease REF
Regorafenib DMHSY1I Moderate Decreased metabolism of Irinotecan caused by Regorafenib mediated inhibition of UGT. Colorectal cancer [2B91] [124]
Coadministration of a Drug Treating the Disease Different from Irinotecan (Comorbidity)
DDI Drug Name DDI Drug ID Severity Mechanism Comorbidity REF
Metreleptin DM1NOEK Moderate Increased metabolism of Irinotecan caused by Metreleptin mediated induction of CYP450 enzyme. Acute diabete complication [5A2Y] [125]
Ivosidenib DM8S6T7 Moderate Increased metabolism of Irinotecan caused by Ivosidenib mediated induction of CYP450 enzyme. Acute myeloid leukaemia [2A60] [125]
Midostaurin DMI6E0R Moderate Decreased clearance of Irinotecan due to the transporter inhibition by Midostaurin. Acute myeloid leukaemia [2A60] [126]
Arn-509 DMT81LZ Major Increased metabolism of Irinotecan caused by Arn-509 mediated induction of CYP450 enzyme. Acute myeloid leukaemia [2A60] [125]
Gilteritinib DMWQ4MZ Moderate Decreased clearance of Irinotecan due to the transporter inhibition by Gilteritinib. Acute myeloid leukaemia [2A60] [127]
Dronedarone DMA8FS5 Moderate Decreased metabolism of Irinotecan caused by Dronedarone mediated inhibition of CYP450 enzyme. Angina pectoris [BA40] [124]
Nifedipine DMSVOZT Moderate Decreased metabolism of Irinotecan caused by Nifedipine mediated inhibition of CYP450 enzyme. Angina pectoris [BA40] [124]
Methylphenobarbital DMDSWAG Moderate Increased metabolism of Irinotecan caused by Methylphenobarbital mediated induction of CYP450 enzyme. Anxiety disorder [6B00-6B0Z] [128]
Posaconazole DMUL5EW Major Decreased metabolism of Irinotecan caused by Posaconazole mediated inhibition of CYP450 enzyme. Aspergillosis [1F20] [124]
Roflumilast DMPGHY8 Moderate Additive immunosuppressive effects by the combination of Irinotecan and Roflumilast. Asthma [CA23] [126]
Ofloxacin DM0VQN3 Minor Decreased absorption of Irinotecan due to intestinal mucosa variation caused by Ofloxacin. Bacterial infection [1A00-1C4Z] [129]
Dalfopristin DM4LTKV Moderate Decreased metabolism of Irinotecan caused by Dalfopristin mediated inhibition of CYP450 enzyme. Bacterial infection [1A00-1C4Z] [127]
Clarithromycin DM4M1SG Major Decreased metabolism of Irinotecan caused by Clarithromycin mediated inhibition of CYP450 enzyme. Bacterial infection [1A00-1C4Z] [124]
Sparfloxacin DMB4HCT Minor Decreased absorption of Irinotecan due to intestinal mucosa variation caused by Sparfloxacin. Bacterial infection [1A00-1C4Z] [129]
Gemifloxacin DMHT34O Minor Decreased absorption of Irinotecan due to intestinal mucosa variation caused by Gemifloxacin. Bacterial infection [1A00-1C4Z] [129]
Norfloxacin DMIZ6W2 Minor Decreased absorption of Irinotecan due to intestinal mucosa variation caused by Norfloxacin. Bacterial infection [1A00-1C4Z] [129]
ABT-492 DMJFD2I Minor Decreased absorption of Irinotecan due to intestinal mucosa variation caused by ABT-492. Bacterial infection [1A00-1C4Z] [129]
Levofloxacin DMS60RB Minor Decreased absorption of Irinotecan due to intestinal mucosa variation caused by Levofloxacin. Bacterial infection [1A00-1C4Z] [129]
Troleandomycin DMUZNIG Major Decreased metabolism of Irinotecan caused by Troleandomycin mediated inhibition of CYP450 enzyme. Bacterial infection [1A00-1C4Z] [124]
Lomefloxacin DMVRH9C Minor Decreased absorption of Irinotecan due to intestinal mucosa variation caused by Lomefloxacin. Bacterial infection [1A00-1C4Z] [129]
Telithromycin DMZ4P3A Major Decreased metabolism of Irinotecan caused by Telithromycin mediated inhibition of CYP450 enzyme. Bacterial infection [1A00-1C4Z] [124]
Ag-221 DMS0ZBI Moderate Decreased clearance of Irinotecan due to the transporter inhibition by Ag-221. BCR-ABL1-negative chronic myeloid leukaemia [2A41] [127]
Pexidartinib DMS2J0Z Moderate Increased metabolism of Irinotecan caused by Pexidartinib mediated induction of CYP450 enzyme. Bone/articular cartilage neoplasm [2F7B] [125]
Lapatinib DM3BH1Y Moderate Decreased metabolism of Irinotecan caused by Lapatinib mediated inhibition of CYP450 enzyme. Breast cancer [2C60-2C6Y] [124]
Tucatinib DMBESUA Major Decreased metabolism of Irinotecan caused by Tucatinib mediated inhibition of CYP450 enzyme. Breast cancer [2C60-2C6Y] [124]
Palbociclib DMD7L94 Moderate Decreased metabolism of Irinotecan caused by Palbociclib mediated inhibition of CYP450 enzyme. Breast cancer [2C60-2C6Y] [124]
PF-04449913 DMSB068 Moderate Decreased clearance of Irinotecan due to the transporter inhibition by PF-04449913. Chronic myelomonocytic leukaemia [2A40] [126]
Phenylbutazone DMAYL0T Moderate Increased metabolism of Irinotecan caused by Phenylbutazone mediated induction of CYP450 enzyme. Chronic pain [MG30] [125]
Atracurium DM42HXN Minor Antagonize the effect of Irinotecan when combined with Atracurium. Corneal disease [9A76-9A78] [130]
Mivacurium DM473VD Minor Antagonize the effect of Irinotecan when combined with Mivacurium. Corneal disease [9A76-9A78] [130]
Pancuronium DMB0VY8 Minor Antagonize the effect of Irinotecan when combined with Pancuronium. Corneal disease [9A76-9A78] [130]
Tubocurarine DMBZIVP Minor Antagonize the effect of Irinotecan when combined with Tubocurarine. Corneal disease [9A76-9A78] [130]
Mifepristone DMGZQEF Major Decreased metabolism of Irinotecan caused by Mifepristone mediated inhibition of CYP450 enzyme. Cushing syndrome [5A70] [124]
Osilodrostat DMIJC9X Moderate Decreased metabolism of Irinotecan caused by Osilodrostat mediated inhibition of CYP450 enzyme. Cushing syndrome [5A70] [124]
Lumacaftor DMCLWDJ Major Increased metabolism of Irinotecan caused by Lumacaftor mediated induction of CYP450 enzyme. Cystic fibrosis [CA25] [131]
Ivacaftor DMZC1HS Moderate Decreased metabolism of Irinotecan caused by Ivacaftor mediated inhibition of CYP450 enzyme. Cystic fibrosis [CA25] [124]
MK-8228 DMOB58Q Moderate Decreased metabolism of Irinotecan caused by MK-8228 mediated inhibition of CYP450 enzyme. Cytomegaloviral disease [1D82] [124]
Nefazodone DM4ZS8M Major Decreased metabolism of Irinotecan caused by Nefazodone mediated inhibition of CYP450 enzyme. Depression [6A70-6A7Z] [124]
Primidone DM0WX6I Major Increased metabolism of Irinotecan caused by Primidone mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [125]
Felbamate DM1V5ZS Moderate Increased metabolism of Irinotecan caused by Felbamate mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [125]
Oxcarbazepine DM5PU6O Moderate Increased metabolism of Irinotecan caused by Oxcarbazepine mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [125]
Cenobamate DMGOVHA Moderate Increased metabolism of Irinotecan caused by Cenobamate mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [125]
Stiripentol DMMSDOY Moderate Decreased metabolism of Irinotecan caused by Stiripentol mediated inhibition of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [124]
Fosphenytoin DMOX3LB Major Increased metabolism of Irinotecan caused by Fosphenytoin mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [125]
Rufinamide DMWE60C Moderate Increased metabolism of Irinotecan caused by Rufinamide mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [125]
Phenobarbital DMXZOCG Major Increased metabolism of Irinotecan caused by Phenobarbital mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [125]
Eslicarbazepine DMZREFQ Moderate Increased metabolism of Irinotecan caused by Eslicarbazepine mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [125]
Tazemetostat DMWP1BH Moderate Increased metabolism of Irinotecan caused by Tazemetostat mediated induction of CYP450 enzyme. Follicular lymphoma [2A80] [125]
Itraconazole DMCR1MV Major Decreased metabolism of Irinotecan caused by Itraconazole mediated inhibition of CYP450 enzyme. Fungal infection [1F29-1F2F] [124]
Miconazole DMPMYE8 Moderate Decreased metabolism of Irinotecan caused by Miconazole mediated inhibition of CYP450 enzyme. Fungal infection [1F29-1F2F] [124]
Ketoconazole DMPZI3Q Major Decreased metabolism of Irinotecan caused by Ketoconazole mediated inhibition of CYP450 enzyme. Fungal infection [1F29-1F2F] [124]
Sulfinpyrazone DMEV954 Moderate Increased metabolism of Irinotecan caused by Sulfinpyrazone mediated induction of CYP450 enzyme. Gout [FA25] [125]
Boceprevir DMBSHMF Major Decreased metabolism of Irinotecan caused by Boceprevir mediated inhibition of CYP450 enzyme. Hepatitis virus infection [1E50-1E51] [124]
Telaprevir DMMRV29 Major Decreased metabolism of Irinotecan caused by Telaprevir mediated inhibition of CYP450 enzyme. Hepatitis virus infection [1E50-1E51] [124]
Isoniazid DM5JVS3 Moderate Decreased metabolism of Irinotecan caused by Isoniazid mediated inhibition of CYP450 enzyme. HIV-infected patients with tuberculosis [1B10-1B14] [124]
Rifampin DMA8J1G Major Increased metabolism of Irinotecan caused by Rifampin mediated induction of CYP450 enzyme. HIV-infected patients with tuberculosis [1B10-1B14] [131]
Rifapentine DMCHV4I Major Increased metabolism of Irinotecan caused by Rifapentine mediated induction of CYP450 enzyme. HIV-infected patients with tuberculosis [1B10-1B14] [125]
Fosamprenavir DM4W9B3 Major Decreased metabolism of Irinotecan caused by Fosamprenavir mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [124]
Fostemsavir DM50ILT Moderate Decreased clearance of Irinotecan due to the transporter inhibition by Fostemsavir. Human immunodeficiency virus disease [1C60-1C62] [132]
Cobicistat DM6L4H2 Major Decreased metabolism of Irinotecan caused by Cobicistat mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [124]
Saquinavir DMG814N Major Decreased metabolism of Irinotecan caused by Saquinavir mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [124]
Etravirine DMGV8QU Moderate Increased metabolism of Irinotecan caused by Etravirine mediated induction of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [125]
Darunavir DMN3GCH Moderate Decreased metabolism of Irinotecan caused by Darunavir mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [124]
Atazanavir DMSYRBX Major Decreased metabolism of Irinotecan caused by Atazanavir mediated inhibition of UGT. Human immunodeficiency virus disease [1C60-1C62] [124]
Bempedoic acid DM1CI9R Moderate Decreased clearance of Irinotecan due to the transporter inhibition by Bempedoic acid. Hyper-lipoproteinaemia [5C80] [133]
Gemfibrozil DMD8Q3J Major Decreased metabolism of Irinotecan caused by Gemfibrozil mediated inhibition of UGT. Hyper-lipoproteinaemia [5C80] [127]
Teriflunomide DMQ2FKJ Major Additive immunosuppressive effects by the combination of Irinotecan and Teriflunomide. Hyper-lipoproteinaemia [5C80] [134]
BMS-201038 DMQTAGO Moderate Decreased metabolism of Irinotecan caused by BMS-201038 mediated inhibition of CYP450 enzyme. Hyper-lipoproteinaemia [5C80] [124]
Conivaptan DM1V329 Major Decreased metabolism of Irinotecan caused by Conivaptan mediated inhibition of CYP450 enzyme. Hypo-osmolality/hyponatraemia [5C72] [124]
Berotralstat DMWA2DZ Moderate Decreased metabolism of Irinotecan caused by Berotralstat mediated inhibition of CYP450 enzyme. Innate/adaptive immunodeficiency [4A00] [124]
Amobarbital DM0GQ8N Moderate Increased metabolism of Irinotecan caused by Amobarbital mediated induction of CYP450 enzyme. Insomnia [7A00-7A0Z] [125]
Denosumab DMNI0KO Moderate Additive myelosuppressive effects by the combination of Irinotecan and Denosumab. Low bone mass disorder [FB83] [135]
Crizotinib DM4F29C Moderate Decreased metabolism of Irinotecan caused by Crizotinib mediated inhibition of CYP450 enzyme. Lung cancer [2C25] [124]
Ceritinib DMB920Z Major Decreased metabolism of Irinotecan caused by Ceritinib mediated inhibition of CYP450 enzyme. Lung cancer [2C25] [124]
PF-06463922 DMKM7EW Moderate Increased metabolism of Irinotecan caused by PF-06463922 mediated induction of CYP450 enzyme. Lung cancer [2C25] [125]
Capmatinib DMYCXKL Moderate Decreased clearance of Irinotecan due to the transporter inhibition by Capmatinib. Lung cancer [2C25] [136]
Selpercatinib DMZR15V Moderate Decreased metabolism of Irinotecan caused by Selpercatinib mediated inhibition of CYP450 enzyme. Lung cancer [2C25] [124]
Idelalisib DM602WT Major Decreased metabolism of Irinotecan caused by Idelalisib mediated inhibition of CYP450 enzyme. Mature B-cell leukaemia [2A82] [124]
Vemurafenib DM62UG5 Moderate Increased metabolism of Irinotecan caused by Vemurafenib mediated induction of CYP450 enzyme. Melanoma [2C30] [125]
Dabrafenib DMX6OE3 Moderate Increased metabolism of Irinotecan caused by Dabrafenib mediated induction of CYP450 enzyme. Melanoma [2C30] [126]
Lasmiditan DMXLVDT Moderate Decreased clearance of Irinotecan due to the transporter inhibition by Lasmiditan. Migraine [8A80] [137]
Exjade DMHPRWG Moderate Increased metabolism of Irinotecan caused by Exjade mediated induction of CYP450 enzyme. Mineral absorption/transport disorder [5C64] [125]
Thalidomide DM70BU5 Major Additive thrombogenic effects by the combination of Irinotecan and Thalidomide. Multiple myeloma [2A83] [138]
Tecfidera DM2OVDT Moderate Additive immunosuppressive effects by the combination of Irinotecan and Tecfidera. Multiple sclerosis [8A40] [139]
Siponimod DM2R86O Major Additive immunosuppressive effects by the combination of Irinotecan and Siponimod. Multiple sclerosis [8A40] [127]
Fingolimod DM5JVAN Major Additive immunosuppressive effects by the combination of Irinotecan and Fingolimod. Multiple sclerosis [8A40] [140]
Ocrelizumab DMEZ2KH Moderate Additive immunosuppressive effects by the combination of Irinotecan and Ocrelizumab. Multiple sclerosis [8A40] [141]
Ozanimod DMT6AM2 Major Additive immunosuppressive effects by the combination of Irinotecan and Ozanimod. Multiple sclerosis [8A40] [126]
Nilotinib DM7HXWT Moderate Decreased metabolism of Irinotecan caused by Nilotinib mediated inhibition of CYP450 enzyme. Myeloproliferative neoplasm [2A20] [124]
Dasatinib DMJV2EK Moderate Decreased metabolism of Irinotecan caused by Dasatinib mediated inhibition of CYP450 enzyme. Myeloproliferative neoplasm [2A20] [124]
Omacetaxine mepesuccinate DMPU2WX Moderate Additive immunosuppressive effects by the combination of Irinotecan and Omacetaxine mepesuccinate. Myeloproliferative neoplasm [2A20] [142]
Rolapitant DM8XP26 Moderate Decreased clearance of Irinotecan due to the transporter inhibition by Rolapitant. Nausea/vomiting [MD90] [143]
Netupitant DMEKAYI Moderate Decreased metabolism of Irinotecan caused by Netupitant mediated inhibition of CYP450 enzyme. Nausea/vomiting [MD90] [127]
Entrectinib DMMPTLH Moderate Decreased metabolism of Irinotecan caused by Entrectinib mediated inhibition of CYP450 enzyme. Non-small cell lung cancer [2C25] [124]
Rucaparib DM9PVX8 Moderate Decreased metabolism of Irinotecan caused by Rucaparib mediated inhibition of CYP450 enzyme. Ovarian cancer [2C73] [124]
Abametapir DM2RX0I Moderate Decreased metabolism of Irinotecan caused by Abametapir mediated inhibition of CYP450 enzyme. Pediculosis [1G00] [144]
Lefamulin DME6G97 Moderate Decreased metabolism of Irinotecan caused by Lefamulin mediated inhibition of CYP450 enzyme. Pneumonia [CA40] [145]
Lonafarnib DMGM2Z6 Major Decreased metabolism of Irinotecan caused by Lonafarnib mediated inhibition of CYP450 enzyme. Premature ageing appearance [LD2B] [124]
ABIRATERONE DM8V75C Moderate Decreased metabolism of Irinotecan caused by ABIRATERONE mediated inhibition of CYP450 enzyme. Prostate cancer [2C82] [124]
Enzalutamide DMGL19D Major Increased metabolism of Irinotecan caused by Enzalutamide mediated induction of CYP450 enzyme. Prostate cancer [2C82] [125]
Darolutamide DMV7YFT Moderate Decreased clearance of Irinotecan due to the transporter inhibition by Darolutamide. Prostate cancer [2C82] [146]
Bicalutamide DMZMSPF Moderate Decreased metabolism of Irinotecan caused by Bicalutamide mediated inhibition of CYP450 enzyme. Prostate cancer [2C82] [124]
Temsirolimus DMS104F Moderate Increased plasma concentrations of Irinotecan and Temsirolimus due to competitive inhibition of the same metabolic pathway. Renal cell carcinoma [2C90] [147]
Gatifloxacin DMSL679 Minor Decreased absorption of Irinotecan due to intestinal mucosa variation caused by Gatifloxacin. Respiratory infection [CA07-CA4Z] [129]
Canakinumab DM8HLO5 Moderate Additive immunosuppressive effects by the combination of Irinotecan and Canakinumab. Rheumatoid arthritis [FA20] [148]
Rilonacept DMGLUQS Moderate Additive immunosuppressive effects by the combination of Irinotecan and Rilonacept. Rheumatoid arthritis [FA20] [148]
Golimumab DMHZV7X Major Additive immunosuppressive effects by the combination of Irinotecan and Golimumab. Rheumatoid arthritis [FA20] [149]
Dexamethasone DMMWZET Moderate Increased metabolism of Irinotecan caused by Dexamethasone mediated induction of CYP450 enzyme. Rheumatoid arthritis [FA20] [125]
Leflunomide DMR8ONJ Major Additive immunosuppressive effects by the combination of Irinotecan and Leflunomide. Rheumatoid arthritis [FA20] [134]
Anthrax vaccine DM9GSWY Moderate Antagonize the effect of Irinotecan when combined with Anthrax vaccine. Sepsis [1G40-1G41] [150]
Voxelotor DMCS6M5 Moderate Decreased metabolism of Irinotecan caused by Voxelotor mediated inhibition of CYP450 enzyme. Sickle-cell disorder [3A51] [124]
Telotristat ethyl DMDIYFZ Moderate Increased metabolism of Irinotecan caused by Telotristat ethyl mediated induction of CYP450 enzyme. Small intestine developmental anomaly [DA90] [126]
Larotrectinib DM26CQR Moderate Decreased metabolism of Irinotecan caused by Larotrectinib mediated inhibition of CYP450 enzyme. Solid tumour/cancer [2A00-2F9Z] [124]
Armodafinil DMGB035 Moderate Increased metabolism of Irinotecan caused by Armodafinil mediated induction of CYP450 enzyme. Solid tumour/cancer [2A00-2F9Z] [125]
LEE011 DMMX75K Moderate Decreased metabolism of Irinotecan caused by LEE011 mediated inhibition of CYP450 enzyme. Solid tumour/cancer [2A00-2F9Z] [124]
Pitolisant DM8RFNJ Moderate Accelerated clearance of Irinotecan due to the transporter induction by Pitolisant. Somnolence [MG42] [126]
Fostamatinib DM6AUHV Moderate Decreased clearance of Irinotecan due to the transporter inhibition by Fostamatinib. Thrombocytopenia [3B64] [151]
Eltrombopag DMOGFIX Moderate Decreased clearance of Irinotecan due to the transporter inhibition by Eltrombopag. Thrombocytopenia [3B64] [152]
Brilinta DMBR01X Moderate Decreased metabolism of Irinotecan caused by Brilinta mediated inhibition of CYP450 enzyme. Thrombosis [DB61-GB90] [124]
Pipecuronium DM5F84A Minor Antagonize the effect of Irinotecan when combined with Pipecuronium. Tonus and reflex abnormality [MB47] [130]
Doxacurium DMKE7L9 Minor Antagonize the effect of Irinotecan when combined with Doxacurium. Tonus and reflex abnormality [MB47] [130]
Vecuronium DMP0UK2 Minor Antagonize the effect of Irinotecan when combined with Vecuronium. Tonus and reflex abnormality [MB47] [130]
Sirolimus DMGW1ID Moderate Increased plasma concentrations of Irinotecan and Sirolimus due to competitive inhibition of the same metabolic pathway. Transplant rejection [NE84] [147]
Azathioprine DMMZSXQ Moderate Additive myelosuppressive effects by the combination of Irinotecan and Azathioprine. Transplant rejection [NE84] [127]
Tacrolimus DMZ7XNQ Moderate Increased plasma concentrations of Irinotecan and Tacrolimus due to competitive inhibition of the same metabolic pathway. Transplant rejection [NE84] [147]
Cinoxacin DM4EWNS Minor Decreased absorption of Irinotecan due to intestinal mucosa variation caused by Cinoxacin. Urinary tract infection [GC08] [129]
Nalidixic acid DMRM0JV Minor Decreased absorption of Irinotecan due to intestinal mucosa variation caused by Nalidixic acid. Urinary tract infection [GC08] [129]
Elagolix DMB2C0E Moderate Increased metabolism of Irinotecan caused by Elagolix mediated induction of CYP450 enzyme. Uterine fibroid [2E86] [125]
Amiodarone DMUTEX3 Moderate Decreased metabolism of Irinotecan caused by Amiodarone mediated inhibition of CYP450 enzyme. Ventricular tachyarrhythmia [BC71] [124]
Ganciclovir DM1MBYQ Moderate Additive myelosuppressive effects by the combination of Irinotecan and Ganciclovir. Virus infection [1A24-1D9Z] [127]
Valganciclovir DMS2IUH Moderate Additive myelosuppressive effects by the combination of Irinotecan and Valganciclovir. Virus infection [1A24-1D9Z] [127]
⏷ Show the Full List of 131 DDI Information of This Drug

References

1 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 6823).
2 New drugs for the treatment of cancer, 1990-2001. Isr Med Assoc J. 2002 Dec;4(12):1124-31.
3 FDA approval: ado-trastuzumab emtansine for the treatment of patients with HER2-positive metastatic breast cancer. Clin Cancer Res. 2014 Sep 1;20(17):4436-41.
4 BDDCS applied to over 900 drugs
5 Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds
6 Estimating the safe starting dose in phase I clinical trials and no observed effect level based on QSAR modeling of the human maximum recommended daily dose
7 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
8 Celecoxib upregulates multidrug resistance proteins in colon cancer: lack of synergy with standard chemotherapy. Curr Cancer Drug Targets. 2008 Aug;8(5):414-20.
9 Intestinal transport of irinotecan in Caco-2 cells and MDCK II cells overexpressing efflux transporters Pgp, cMOAT, and MRP1. Drug Metab Dispos. 2002 Jul;30(7):763-70.
10 P-glycoprotein, but not multidrug resistance protein 4, plays a role in the systemic clearance of irinotecan and SN-38 in mice. Drug Metab Lett. 2010 Dec;4(4):195-201.
11 ATP-Dependent efflux of CPT-11 and SN-38 by the multidrug resistance protein (MRP) and its inhibition by PAK-104P. Mol Pharmacol. 1999 May;55(5):921-8.
12 Cyclosporin A, tacrolimus and sirolimus are potent inhibitors of the human breast cancer resistance protein (ABCG2) and reverse resistance to mitoxantrone and topotecan. Cancer Chemother Pharmacol. 2006 Sep;58(3):374-83.
13 Irinotecan and its active metabolite, SN-38: review of bioanalytical methods and recent update from clinical pharmacology perspectives. Biomed Chromatogr. 2010 Jan;24(1):104-23.
14 Pharmacogenetics of irinotecan metabolism and transport: an update. Toxicol In Vitro. 2006 Mar;20(2):163-75.
15 Drugs that may have potential CYP2B6 interactions.
16 Drug Interactions Flockhart Table
17 Hydrolysis of irinotecan and its oxidative metabolites, 7-ethyl-10-[4-N-(5-aminopentanoic acid)-1-piperidino] carbonyloxycamptothecin and 7-ethyl-10-[4-(1-piperidino)-1-amino]-carbonyloxycamptothecin, by human carboxylesterases CES1A1, CES2, and a newly expressed carboxylesterase isoenzyme, CES3. Drug Metab Dispos. 2004 May;32(5):505-11.
18 Involvement of beta-glucuronidase in intestinal microflora in the intestinal toxicity of the antitumor camptothecin derivative irinotecan hydrochloride (CPT-11) in rats. Cancer Res. 1996 Aug 15;56(16):3752-7.
19 Expression levels and activation of a PXR variant are directly related to drug resistance in osteosarcoma cell lines. Cancer. 2007 Mar 1;109(5):957-65.
20 Contribution of human hepatic cytochrome P450 isoforms to regioselective hydroxylation of steroid hormones. Xenobiotica. 1998 Jun;28(6):539-47.
21 Comprehensive evaluation of tamoxifen sequential biotransformation by the human cytochrome P450 system in vitro: prominent roles for CYP3A and CYP2D6. J Pharmacol Exp Ther. 2004 Sep;310(3):1062-75.
22 Isoform-specific regulation of cytochromes P450 expression by estradiol and progesterone. Drug Metab Dispos. 2013 Feb;41(2):263-9.
23 Metabolic interactions between acetaminophen (paracetamol) and two flavonoids, luteolin and quercetin, through in-vitro inhibition studies. J Pharm Pharmacol. 2017 Dec;69(12):1762-1772.
24 Potent mechanism-based inhibition of CYP3A4 by imatinib explains its liability to interact with CYP3A4 substrates. Br J Pharmacol. 2012 Apr;165(8):2787-98.
25 Effects of morin on the pharmacokinetics of etoposide in rats. Biopharm Drug Dispos. 2007 Apr;28(3):151-6.
26 The metabolism of zidovudine by human liver microsomes in vitro: formation of 3'-amino-3'-deoxythymidine. Biochem Pharmacol. 1994 Jul 19;48(2):267-76.
27 Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
28 Drug related genetic polymorphisms affecting adverse reactions to methotrexate, vinblastine, doxorubicin and cisplatin in patients with urothelial cancer. J Urol. 2008 Dec;180(6):2389-95.
29 Human prostate CYP3A5: identification of a unique 5'-untranslated sequence and characterization of purified recombinant protein. Biochem Biophys Res Commun. 1999 Jul 14;260(3):676-81.
30 Polymorphisms in cytochrome P4503A5 (CYP3A5) may be associated with race and tumor characteristics, but not metabolism and side effects of tamoxifen in breast cancer patients. Cancer Lett. 2005 Jan 10;217(1):61-72.
31 Induction of hepatic CYP2E1 by a subtoxic dose of acetaminophen in rats: increase in dichloromethane metabolism and carboxyhemoglobin elevation. Drug Metab Dispos. 2007 Oct;35(10):1754-8.
32 Urinary 6 beta-hydroxycortisol excretion in rheumatoid arthritis. Br J Rheumatol. 1997 Jan;36(1):54-8.
33 Clinical pharmacokinetics of imatinib. Clin Pharmacokinet. 2005;44(9):879-94.
34 Kinetics and regulation of cytochrome P450-mediated etoposide metabolism. Drug Metab Dispos. 2004 Sep;32(9):993-1000.
35 Differential mechanism-based inhibition of CYP3A4 and CYP3A5 by verapamil. Drug Metab Dispos. 2005 May;33(5):664-71.
36 The role of cytochrome P450 3A (CYP3A) isoform(s) in oxidative metabolism of testosterone and benzphetamine in human adult and fetal liver. J Steroid Biochem Mol Biol. 1993 Jan;44(1):61-7.
37 Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev. 2002 Feb-May;34(1-2):83-448.
38 Prediction of cytochrome P450 3A inhibition by verapamil enantiomers and their metabolites. Drug Metab Dispos. 2004 Feb;32(2):259-66.
39 The role of human cytochrome P450 enzymes in the formation of 2-hydroxymetronidazole: CYP2A6 is the high affinity (low Km) catalyst. Drug Metab Dispos. 2013 Sep;41(9):1686-94.
40 Drug Development and Drug Interactions: Table of Substrates, Inhibitors and Inducers.
41 Effect of tamoxifen on the enzymatic activity of human cytochrome CYP2B6. J Pharmacol Exp Ther. 2002 Jun;301(3):945-52.
42 Hepatic metabolism of diclofenac: role of human CYP in the minor oxidative pathways. Biochem Pharmacol. 1999 Sep 1;58(5):787-96.
43 Characterization of the oxidative metabolites of 17beta-estradiol and estrone formed by 15 selectively expressed human cytochrome p450 isoforms. Endocrinology. 2003 Aug;144(8):3382-98.
44 Insights into CYP2B6-mediated drug-drug interactions. Acta Pharm Sin B. 2016 Sep;6(5):413-425.
45 Involvement of human cytochrome P450 2B6 in the omega- and 4-hydroxylation of the anesthetic agent propofol. Xenobiotica. 2007 Jul;37(7):717-24.
46 Nicotine and 4-(methylnitrosamino)-1-(3-pyridyl)-butanone metabolism by cytochrome P450 2B6. Drug Metab Dispos. 2005 Dec;33(12):1760-4.
47 PharmGKB summary: phenytoin pathway. Pharmacogenet Genomics. 2012 Jun;22(6):466-70.
48 Application of the relative activity factor approach in scaling from heterologously expressed cytochromes p450 to human liver microsomes: studies on amitriptyline as a model substrate. J Pharmacol Exp Ther. 2001 Apr;297(1):326-37.
49 Absorption and cleavage of enalapril, a carboxyl ester prodrug, in the rat intestine: in vitro, in situ intestinal perfusion and portal vein cannulation models. Biopharm Drug Dispos. 2015 Sep;36(6):385-397.
50 Different hydrolases involved in bioactivation of prodrug-type angiotensin receptor blockers: carboxymethylenebutenolidase and carboxylesterase 1. Drug Metab Dispos. 2013 Nov;41(11):1888-95.
51 Effect of carboxylesterase 1 c.428G>A single nucleotide variation on the pharmacokinetics of quinapril and enalapril. Br J Clin Pharmacol. 2015 Nov;80(5):1131-8.
52 Methylphenidate is stereoselectively hydrolyzed by human carboxylesterase CES1A1. J Pharmacol Exp Ther. 2004 Aug;310(2):469-76.
53 Mechanism of activation of PSI-7851 and its diastereoisomer PSI-7977. J Biol Chem. 2010 Nov 5;285(45):34337-47.
54 Investigation of the metabolism of rufinamide and its interaction with valproate. Drug Metab Lett. 2011 Dec;5(4):280-9.
55 Dexmethylphenidate hydrochloride in the treatment of attention deficit hyperactivity disorder. Neuropsychiatr Dis Treat. 2006 Dec;2(4):467-73.
56 Summary of FDA-approved anticancer cytotoxic drugs at May 2019.
57 Pharmacogenomics of novel direct oral anticoagulants: newly identified genes and genetic variants. J Pers Med. 2019 Jan 17;9(1). pii: E7.
58 Conventional liquid chromatography/triple quadrupole mass spectrometry based metabolite identification and semi-quantitative estimation approach in the investigation of in vitro dabigatran etexilate metabolism. Anal Bioanal Chem. 2013 Feb;405(5):1695-704.
59 Pyrethroids: mammalian metabolism and toxicity. J Agric Food Chem. 2011 Apr 13;59(7):2786-91.
60 In vitro metabolism of dexamethasone cipecilate, a novel synthetic corticosteroid, in human liver and nasal mucosa. Xenobiotica. 2011 Oct;41(10):874-84.
61 Long-term administration of conjugated estrogen and bazedoxifene decreased murine fecal beta-glucuronidase activity without impacting overall microbiome community. Sci Rep. 2018 May 25;8(1):8166.
62 Metabolism of irinotecan and its active metabolite SN-38 by intestinal microflora in rats. Oncol Rep. 2008 Oct;20(4):727-30.
63 Bidirectional interactions between indomethacin and the murine intestinal microbiota. Elife. 2015 Dec 23;4:e08973.
64 Bacterial beta-glucuronidase inhibition protects mice against enteropathy induced by indomethacin, ketoprofen or diclofenac: mode of action and pharmacokinetics. Xenobiotica. 2014 Jan;44(1):28-35.
65 The role of bioreductive activation of doxorubicin in cytotoxic activity against leukaemia HL60-sensitive cell line and its multidrug-resistant sublines. Br J Cancer. 2005 Jul 11;93(1):89-97.
66 Transport of methotrexate (MTX) and folates by multidrug resistance protein (MRP) 3 and MRP1: effect of polyglutamylation on MTX transport. Cancer Res. 2001 Oct 1;61(19):7225-32.
67 Folate concentration dependent transport activity of the Multidrug Resistance Protein 1 (ABCC1). Biochem Pharmacol. 2004 Apr 15;67(8):1541-8.
68 Hammerhead ribozyme against gamma-glutamylcysteine synthetase sensitizes human colonic cancer cells to cisplatin by down-regulating both the glutathione synthesis and the expression of multidrug resistance proteins. Cancer Gene Ther. 2001 Oct;8(10):803-14.
69 Multidrug resistance-associated protein-1 functional activity in Calu-3 cells. J Pharmacol Exp Ther. 2001 Sep;298(3):1199-205.
70 Human intestinal transporter database: QSAR modeling and virtual profiling of drug uptake, efflux and interactions. Pharm Res. 2013 Apr;30(4):996-1007.
71 Structural determinants of substrate specificity differences between human multidrug resistance protein (MRP) 1 (ABCC1) and MRP3 (ABCC3). Drug Metab Dispos. 2008 Dec;36(12):2571-81.
72 Evaluation of transport of common antiepileptic drugs by human multidrug resistance-associated proteins (MRP1, 2 and 5) that are overexpressed in pharmacoresistant epilepsy. Neuropharmacology. 2010 Jun;58(7):1019-32.
73 Vinblastine and sulfinpyrazone export by the multidrug resistance protein MRP2 is associated with glutathione export. Br J Cancer. 2000 Aug;83(3):375-83.
74 Involvement of the drug transporters p glycoprotein and multidrug resistance-associated protein Mrp2 in telithromycin transport. Antimicrob Agents Chemother. 2006 Jan;50(1):80-7.
75 Dose-dependent disposition of methotrexate in Abcc2 and Abcc3 gene knockout murine models. Drug Metab Dispos. 2011 Nov;39(11):2155-61.
76 Mammalian multidrug-resistance proteins (MRPs). Essays Biochem. 2011 Sep 7;50(1):179-207.
77 Enhancing chemosensitivity in oral squamous cell carcinoma by lentivirus vector-mediated RNA interference targeting EGFR and MRP2. Oncol Lett. 2016 Sep;12(3):2107-2114.
78 Multidrug resistance associated protein 2 mediates transport of prostaglandin E2. Liver Int. 2006 Apr;26(3):362-8.
79 Lentivirus-mediated RNAi silencing targeting ABCC2 increasing the sensitivity of a human nasopharyngeal carcinoma cell line against cisplatin. J Transl Med. 2008 Oct 4;6:55.
80 Effect of acetaminophen on expression and activity of rat liver multidrug resistance-associated protein 2 and P-glycoprotein. Biochem Pharmacol. 2004 Aug 15;68(4):791-8.
81 Small intestinal efflux mediated by MRP2 and BCRP shifts sulfasalazine intestinal permeability from high to low, enabling its colonic targeting. Am J Physiol Gastrointest Liver Physiol. 2009 Aug;297(2):G371-7.
82 Delineating the contribution of secretory transporters in the efflux of etoposide using Madin-Darby canine kidney (MDCK) cells overexpressing P-glycoprotein (Pgp), multidrug resistance-associated protein (MRP1), and canalicular multispecific organic anion transporter (cMOAT). Drug Metab Dispos. 2002 Apr;30(4):457-63.
83 Multidrug Resistance-Associated Protein 2 (MRP2) Mediated Transport of Oxaliplatin-Derived Platinum in Membrane Vesicles. PLoS One. 2015 Jul 1;10(7):e0130727.
84 MDR1 (ABCB1) G1199A (Ser400Asn) polymorphism alters transepithelial permeability and sensitivity to anticancer agents. Cancer Chemother Pharmacol. 2009 Jun;64(1):183-8.
85 Mammalian drug efflux transporters of the ATP binding cassette (ABC) family in multidrug resistance: A review of the past decade. Cancer Lett. 2016 Jan 1;370(1):153-64.
86 Folate transporter expression decreases in the human placenta throughout pregnancy and in pre-eclampsia. Pregnancy Hypertens. 2012 Apr;2(2):123-31.
87 Comparative studies on in vitro methods for evaluating in vivo function of MDR1 P-glycoprotein. Pharm Res. 2001 Dec;18(12):1660-8.
88 Antiestrogens and steroid hormones: substrates of the human P-glycoprotein. Biochem Pharmacol. 1994 Jul 19;48(2):287-92.
89 Association of genetic polymorphisms in the influx transporter SLCO1B3 and the efflux transporter ABCB1 with imatinib pharmacokinetics in patients with chronic myeloid leukemia. Ther Drug Monit. 2011 Apr;33(2):244-50.
90 Doxorubicin transport by RALBP1 and ABCG2 in lung and breast cancer. Int J Oncol. 2007 Mar;30(3):717-25.
91 Wild-type breast cancer resistance protein (BCRP/ABCG2) is a methotrexate polyglutamate transporter. Cancer Res. 2003 Sep 1;63(17):5538-43.
92 The effect of low pH on breast cancer resistance protein (ABCG2)-mediated transport of methotrexate, 7-hydroxymethotrexate, methotrexate diglutamate, folic acid, mitoxantrone, topotecan, and resveratrol in in vitro drug transport models. Mol Pharmacol. 2007 Jan;71(1):240-9.
93 Role of BCRP as a biomarker for predicting resistance to 5-fluorouracil in breast cancer. Cancer Chemother Pharmacol. 2009 May;63(6):1103-10.
94 Inhibiting the function of ABCB1 and ABCG2 by the EGFR tyrosine kinase inhibitor AG1478. Biochem Pharmacol. 2009 Mar 1;77(5):781-93.
95 Sterol transport by the human breast cancer resistance protein (ABCG2) expressed in Lactococcus lactis. J Biol Chem. 2003 Jun 6;278(23):20645-51.
96 The phytoestrogen genistein enhances multidrug resistance in breast cancer cell lines by translational regulation of ABC transporters. Cancer Lett. 2016 Jun 28;376(1):165-72.
97 Curcumin inhibits the activity of ABCG2/BCRP1, a multidrug resistance-linked ABC drug transporter in mice. Pharm Res. 2009 Feb;26(2):480-7.
98 Imatinib mesylate (STI571) is a substrate for the breast cancer resistance protein (BCRP)/ABCG2 drug pump. Blood. 2004 Nov 1;104(9):2940-2.
99 Interaction of nonsteroidal anti-inflammatory drugs with multidrug resistance protein (MRP) 2/ABCC2- and MRP4/ABCC4-mediated methotrexate transport. J Pharmacol Exp Ther. 2007 Jan;320(1):229-35.
100 Analysis of methotrexate and folate transport by multidrug resistance protein 4 (ABCC4): MRP4 is a component of the methotrexate efflux system. Cancer Res. 2002 Jun 1;62(11):3144-50.
101 ATP-binding cassette C transporters in human pancreatic carcinoma cell lines. Upregulation in 5-fluorouracil-resistant cells. Pancreatology. 2009;9(1-2):136-44.
102 The human multidrug resistance protein MRP4 functions as a prostaglandin efflux transporter and is inhibited by nonsteroidal antiinflammatory drugs. Proc Natl Acad Sci U S A. 2003 Aug 5;100(16):9244-9.
103 Steroid and bile acid conjugates are substrates of human multidrug-resistance protein (MRP) 4 (ATP-binding cassette C4). Biochem J. 2003 Apr 15;371(Pt 2):361-7.
104 Polymorphisms in multidrug resistance-associated protein gene 4 is associated with outcome in childhood acute lymphoblastic leukemia. Blood. 2009 Aug 13;114(7):1383-6.
105 Role of glutathione in the multidrug resistance protein 4 (MRP4/ABCC4)-mediated efflux of cAMP and resistance to purine analogues. Biochem J. 2002 Feb 1;361(Pt 3):497-503.
106 Oral availability of cefadroxil depends on ABCC3 and ABCC4. Drug Metab Dispos. 2012 Mar;40(3):515-21.
107 The human multidrug resistance protein MRP5 transports folates and can mediate cellular resistance against antifolates. Cancer Res. 2005 May 15;65(10):4425-30.
108 Overexpression of MRP4 (ABCC4) and MRP5 (ABCC5) confer resistance to the nucleoside analogs cytarabine and troxacitabine, but not gemcitabine. Springerplus. 2014 Dec 13;3:732.
109 Cellular export of drugs and signaling molecules by the ATP-binding cassette transporters MRP4 (ABCC4) and MRP5 (ABCC5). Drug Metab Rev. 2005;37(1):253-78.
110 Interdependence of gemcitabine treatment, transporter expression, and resistance in human pancreatic carcinoma cells. Neoplasia. 2010 Sep;12(9):740-7.
111 Hyaluronan export by the ABC transporter MRP5 and its modulation by intracellular cGMP. J Biol Chem. 2007 Jul 20;282(29):20999-1004.
112 Kinetic validation of the use of carboxydichlorofluorescein as a drug surrogate for MRP5-mediated transport. Eur J Pharm Sci. 2006 Apr;27(5):524-32.
113 Role of MRP4 and MRP5 in biology and chemotherapy. AAPS PharmSci. 2002;4(3):E14.
114 The multidrug resistance protein 5 functions as an ATP-dependent export pump for cyclic nucleotides. J Biol Chem. 2000 Sep 29;275(39):30069-74.
115 Luteolin, an emerging anti-cancer flavonoid, poisons eukaryotic DNA topoisomerase I. Biochem J. 2002 Sep 1;366(Pt 2):653-61.
116 Impact of natural products on developing new anti-cancer agents. Chem Rev. 2009 Jul;109(7):3012-43.
117 Clinical pipeline report, company report or official report of GlaxoSmithKline (2009).
118 Characterization of protein kinase chk1 essential for the cell cycle checkpoint after exposure of human head and neck carcinoma A253 cells to a novel topoisomerase I inhibitor BNP1350. Mol Pharmacol.2000 Mar;57(3):453-9.
119 Topoisomerase I inhibitors: camptothecins and beyond. Nat Rev Cancer. 2006 Oct;6(10):789-802.
120 Phase I study of topoisomerase I inhibitor exatecan mesylate (DX-8951f) given as weekly 24-hour infusions three of every four weeks. Clin Cancer Res. 2001 Dec;7(12):3963-70.
121 Edotecarin: a novel topoisomerase I inhibitor. Clin Colorectal Cancer. 2005 May;5(1):27-36.
122 Rubitecan. Expert Opin Investig Drugs. 2006 Jan;15(1):71-9.
123 Nonclinical pharmacokinetics and activity of etirinotecan pegol (NKTR-102), a long-acting topoisomerase 1 inhibitor, in multiple cancer models. Cancer Chemother Pharmacol. 2014 Dec;74(6):1125-37.
124 Canadian Pharmacists Association.
125 Crews KR, Stewart CF, Jones-Wallace D, et al "Altered irinotecan pharmacokinetics in pediatric high-grade glioma patients receiving enzyme-inducing anticonvulsant therapy." Clin Cancer Res 8 (2002): 2202-9. [PMID: 12114421]
126 Cerner Multum, Inc. "UK Summary of Product Characteristics.".
127 Cerner Multum, Inc. "Australian Product Information.".
128 Di YM, Li CG, Xue CC, Zhou SF "Clinical drugs that interact with St. John's wort and implication in drug development." Curr Pharm Des 14 (2008): 1723-42. [PMID: 18673195]
129 Johnson EJ, MacGowan AP, Potter MN, et al "Reduced absorption of oral ciprofloxacin after chemotherapy for haematological malignancy." J Antimicrob Chemother 25 (1990): 837-42. [PMID: 2373666]
130 Product Information. Camptosar (irinotecan). Pharmacia and Upjohn, Kalamazoo, MI.
131 Kuhn JG "Influence of anticonvulsants on the metabolism and elimination of irinotecan. A North American Brain Tumor Consortium preliminary report." Oncology (Williston Park 16(8 Suppl 7) (2002): 33-40. [PMID: 12199631]
132 Product Information. Rukobia (fostemsavir). ViiV Healthcare, Research Triangle Park, NC.
133 Product Information. Nexletol (bempedoic acid). Esperion Therapeutics, Ann Arbor, MI.
134 Product Information. Arava (leflunomide). Hoechst Marion-Roussel Inc, Kansas City, MO.
135 Product Information. Prolia (denosumab). Amgen USA, Thousand Oaks, CA.
136 Product Information. Tabrecta (capmatinib). Novartis Pharmaceuticals, East Hanover, NJ.
137 Product Information. Reyvow (lasmiditan). Lilly, Eli and Company, Indianapolis, IN.
138 Bennett CL, Nebeker JR, Samore MH, et al "The Research on Adverse Drug Events and Reports (RADAR) project." JAMA 293 (2005): 2131-40. [PMID: 15870417]
139 Product Information. Vumerity (diroximel fumarate). Alkermes, Inc, Cambridge, MA.
140 Product Information. Gilenya (fingolimod). Novartis Pharmaceuticals, East Hanover, NJ.
141 Product Information. Ocrevus (ocrelizumab). Genentech, South San Francisco, CA.
142 Product Information. Synribo (omacetaxine). Teva Pharmaceuticals USA, North Wales, PA.
143 Product Information. Varubi (rolapitant). Tesaro Inc., Waltham, MA.
144 Product Information. Xeglyze (abametapir topical). Dr. Reddy's Laboratories Inc, Upper Saddle River, NJ.
145 Product Information. Xenleta (lefamulin). Nabriva Therapeutics US, Inc., King of Prussia, PA.
146 Product Information. Nubeqa (darolutamide). Bayer HealthCare Pharmaceuticals Inc., Whippany, NJ.
147 Product Information. Prograf (tacrolimus). Fujisawa, Deerfield, IL.
148 Product Information. Arcalyst (rilonacept). Regeneron Pharmaceuticals Inc, Tarrytown, NY.
149 Product Information. Cimzia (certolizumab). UCB Pharma Inc, Smyrna, GA.
150 CDC. Centers for Disease Control and Prevention/ "Recommendations of the advisory committtee on immunization practices (ACIP): use of vaccines and immune globulins in persons with altered immunocompetence." MMWR Morb Mortal Wkly Rep 42(RR-04) (1993): 1-18. [PMID: 20300058]
151 Product Information. Tavalisse (fostamatinib). Rigel Pharmaceuticals, South San Francisco, CA.
152 Allred AJ, Bowen CJ, Park JW, et al. "Eltrombopag increases plasma rosuvastatin exposure in healthy volunteers." Br J Clin Pharmacol 72 (2011): 321-9. [PMID: 21434975]